CFT7455 is primarily investigated for its application in oncology, specifically as a targeted protein degrader. It functions as a PROTAC (proteolysis-targeting chimera), designed to induce the degradation of specific disease-causing proteins within cells. Its main application lies in the treatment of certain hormone receptor-positive cancers, particularly advanced or metastatic breast cancer. By promoting the degradation of key signaling proteins involved in tumor growth, CFT7455 offers a potential therapeutic advantage over traditional inhibitors, especially in cases where resistance to standard therapies has developed. It is currently under clinical evaluation to assess its efficacy, safety, and optimal dosing in patients with solid tumors.